OUR

EXPERTS

Science Valley’s management is led by two scientists with over 15 years of international experience in the market and with several world-renowned publications. Since 2018, in light of the best international practices in Clinical Research, scientists Eduardo Ramacciotti (MD, PhD) and Leandro Agati (Pharmacologist, PhD) have been implementing an innovative operational model, attracting partnerships with several companies in the Pharma/Healthcare sector.

EDUARDO RAMACCIOTTI

Co-fundador e CBO (Chief of Board) da SVRI

MD, PhD, Vascular and Endovascular Surgery
Co-founder and CBO (Chief of Board) of Science Valley

Visiting professor at the Loyola University Medical Center (Chicago, USA) with the affiliation of the Departments of Pathology and Pharmacology. Extensive expertise in the cardiovascular area, focus on thrombosis, hemostasis, peripheral artery diseases and drug development. Clinical trialist and mentor from graduate students toPh.D.Programs. His clinical background includes MD, MPH andPh.D.degrees (in thrombosis), with 2 fellowship programs (post-doc) including basic and clinical research at the University of Michigan and Loyola University Medical Center, Chicago, USA.

Strong publication background includes 95 major papers published, 4 book EXECUTIVE SUMMARYs, major oral presentations in medical international meetings. In 2017 Dr. Ramacciotti was given the Outstanding Achievement Award by the NATF / GTF for his contributions in education and research in VTE and PAD. His employment included Global Medical Leading director of Bristol Myers Co R&D in New York from 2010-2014, the direction of basic to late phase clinical research (from bench to bedside) in cardiovascular areas, including the oral anticoagulant apixaban.

LEANDRO BARILE AGATI

Co-founder and CEO of Science Valley

PhD, Pharmacologist and Trialist

Leading the Research Center of Leforte network in the last 7 years; Huge experience in running and designing Randomised Clinical Trials (RCT) -Study director of more than 50 trials; Director of ALS study: PHASE I trial. NCT02987413. Currently running several international RCTs; Ph.D. in Pharmacology at Universidade Estadual PaulistaJúlio de Mesquita Filho (UNESP) and at Department of Psychiatry/University of Illinois at Chicago (UIC).
 
Post-doctorate at Unifesp/Infar in molecular biology and development of antimicrobials with recombinant protein technique. Scientific reviewer of 4 index journals: Clinical and Applied Thrombosis and Hemostasis, ClinicalPharmacology-OMICS, Experimental Physiology and General and Comparative Endocrinology. Speaker andconsultant for Daiichi-SankyoandBayer, rivaroxaban (Real World data).
An entrepreneur, with a creative and innovating mind for new approaches in the R&D Healthcare area, bringing future solutions to our present scenario.